Skip to content
OpenCapital
Get started

Iovance Biotherapeutics, Inc. IOVA Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$359M+63.2%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
——
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
——

Other financials

Income statement

See full
Revenue$71.4M+44.8%
Gross profit$28.9M+338%
Operating income-$81.0M+33.1%
Net income-$79.0M+32.0%
EPS (diluted)-$0.19+47.2%

Balance sheet

See full
Cash & equivalents$196.5M+14.5%
Total debt$46.8M-11.3%
Total equity$721.8M-6.0%
Total assets$925.7M-4.2%

Cash flow

See full
Operating cash flow-$72.1M+30.5%
CapEx$6.6M+6.4%
Free cash flow-$78.7M+28.4%

Valuation

See full
Market cap$1.9B+32.4%

Profitability

See full
Gross margin36.7%+4.1pp
Operating margin-127.2%-31.0pp
Net margin-123.9%-28.4pp
FCF margin-106.8%-27.5pp

Returns & leverage

See full
Return on equity-47.5%-3.7pp
Debt / equity0.1×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s proceeds from sale and maturity of available for sale securities?
Iovance Biotherapeutics, Inc. (IOVA) reported proceeds from sale and maturity of available for sale securities of $74M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s proceeds from sale and maturity of available for sale securities changed year-over-year?
Iovance Biotherapeutics, Inc.'s proceeds from sale and maturity of available for sale securities decreased by 38.3% year-over-year, from $120M to $74M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s proceeds from sale and maturity of available for sale securities has grown at a -14.9% compound annual growth rate (CAGR), from $762.91M to $400M.